TriVascular Merger (Tables)

12 Months Ended

Dec. 31, 2016

Summary of Purchase Consideration Given in Acquisition

The total purchase consideration given related to the acquisition follows:



Cash consideration	$	84,634
Common stock consideration	100,812
Fair value of assumed TriVascular stock warrants	44
Total purchase consideration	$	185,490

Summary of Allocation of Purchase Consideration

The following presents the allocation of the purchase consideration to the assets acquired and liabilities assumed on February 3, 2016 (in thousands):



Cash and cash equivalents	$	24,012
Short-term investments	3,008
Accounts receivable	5,780
Inventories	17,765
Prepaid expenses and other current assets	1,895
Property and equipment	3,152
Intangible assets	46,200
Other assets	317
Accounts payable	(2,214		)
Accrued liabilities and other	(6,450		)
Notes payable	(61		)
Net assets acquired	$	93,404
Goodwill	$	92,086
Total purchase consideration	$	185,490

Schedule of Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the year ended December 31, 2016 are as follows (in thousands):



Balance at January 1, 2016	$	28,685
Goodwill acquired from the Merger	92,086
Foreign currency translation adjustment	(60		)
Balance at December 31, 2016	$	120,711

Summary of Pro Forma Financial Information of Acquisition

The following unaudited pro forma pro forma financial information summarizes the results of operations for the periods indicated as if the TriVascular merger had been completed as of January 1, 2015. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the merger. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up, direct transaction costs relating to the acquisition, the incremental intangible asset amortization to be incurred based on the values of each identifiable intangible asset, and to eliminate interest expense related to legacy TriVascular's former loans, which was repaid upon completion of the TriVascular merger. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the merger had occurred as of January 1, 2015 or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.



	Twelve Months Ended
	December 31,
	2016			2015
Pro forma net sales	$	195,596		$	190,605
Pro forma net loss from continuing operations	(150,054		)	(113,534		)
Pro forma basic and diluted net loss per share	$	(1.82	)	$	(1.40	)